title: Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval.
authors: Department of Hospital Internal Medicine.
authors: Holly
authors: H
authors: Geyer
authors: Keith
authors: K
authors: Cannon
authors: Emily
authors: E
authors: Knight
authors: Veena
authors: V
authors: Fauble
authors: John
authors: J
authors: Camoriano
authors: Robyn
authors: R
authors: Emanuel
authors: Raoul
authors: R
authors: Tibes
authors: Ruben
authors: R
authors: Mesa
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053612:Janus Kinases